对新型冠状病毒实验室检测技术合理应用的再认识

doi:10.3969/j.issn.1673-8640.2022.04.001

检验医学 ›› 2022, Vol. 37 ›› Issue (4): 303-308.DOI: 10.3969/j.issn.1673-8640.2022.04.001

• 专家论坛 • 下一篇

对新型冠状病毒实验室检测技术合理应用的再认识

欧铜, 张兵, 张秀明

深圳市罗湖区人民医院检验科,广东深圳 518001

收稿日期:2022-04-16 修回日期:2022-04-20 出版日期:2022-04-30 发布日期:2022-06-07
通讯作者: 张秀明
作者简介:张秀明,E-mail： zxm0760@163.com。

张秀明,主任技师,硕士生导师、博士后合作导师。深圳市罗湖医院集团副院长兼医学检验中心主任。中国合格评定国家认可委员会医学实验室认可主任评审员,广东省医疗安全协会副会长兼检验医学分会主任委员,广东省医学会检验医学分会副主任委员,《中华检验医学杂志》编委、《临床检验杂志》常务编委,深圳市临床检验质量控制中心副主任,深圳市新型冠状病毒肺炎创新技术与产品验证基地主任。以第一作者或通信作者发表学术论文166篇,其中SCI收录26篇。主编《临床生化检验诊断学》《临床检验方法学评价》《医学实验室ISO 15189认可迎检思路与申请路径》等专著11部。主持或参与国家及省、市级科研课题12项。获省部级科技进步奖6项。拥有国家发明专利和软件版权11项。
欧铜,男,1987年生,博士,副研究员,主要从事基因检测与液体活检研究。
基金资助:
深圳市医学重点学科建设项目(SZXK054)

Re-understanding about the rational application of clinical laboratory determination technologies for COVID-19 diagnosis

OU Tong, ZHANG Bing, ZHANG Xiuming

Department of Clinical Laboratory,Shenzhen Luohu People's Hospital,Shenzhen 518001,Guangdong,China

Received:2022-04-16 Revised:2022-04-20 Online:2022-04-30 Published:2022-06-07
Contact: ZHANG Xiuming

摘要/Abstract

摘要：

新型冠状病毒肺炎（COVID-19）疫情严重危及人类健康和社会经济发展。临床实验室精准的病原学检测是疫情防控的前提。目前,新型冠状病毒实验室检测技术主要包括核酸检测、抗体检测和抗原检测。核酸检测灵敏度高、特异性强,是诊断COVID-19的“金标准”,但对人员、技术、设备、场地等要求高;抗体检测作为核酸检测的补充,可减少漏检,监测疾病进展,但人群普遍接种新型冠状病毒疫苗后会产生“假阳性”;抗原检测方便、快捷,可居家操作,但灵敏度受疾病进程和病毒载量影响大。为了提高大规模核酸检测效率,国家卫生健康委先后推出了5合1、10合1、20合1不同比例的混采检测技术,但因混采管保存液体积成倍增加会导致病毒稀释,有一定的漏检风险,并会使单采复核与流调工作量剧增。随着疫情的持续,病毒株不断变异,实验室检测技术也在不断更新迭代。准确分析、研判现有检测技术的优劣和应用场景,更有利于疫情的科学防控。文章围绕核酸检测“混采”与“混检”、病毒变异对核酸检测性能的影响、核酸检测试剂“内源性”和“外源性”内标的优劣、抗原检测的意义和应用场景、疫苗接种后抗体检测的价值等关键技术问题进行分析,并提出应用建议。

关键词: 新型冠状病毒, 实验室检测, 病毒变异, 分析性能

Abstract:

Corona virus disease 2019（COVID-19） epidemic has seriously endangered human health and economic and social development. Accurate etiological determination in clinical laboratories is a prerequisite for epidemic prevention and control. At present,clinical laboratory determination technologies for severe acute respiratory syndrome coronavirus-2 mainly include nucleic acid,antibody and antigen determinations. Nucleic acid determination is a gold standard for the COVID-19 diagnosis with high sensitivity and specificity,but it has high requirements for personnel technical needs and experimental conditions. Antibody determination can be used as a supplement for nucleic acid determination to reduce missed determination and monitor the disease progress,while universal vaccination will affect the interpretation of antibody determination results,like false positivity. Antigen determination is convenient and fast,which can be operated at home,but its sensitivity is greatly affected by the disease process and viral load. In order to improve the efficiency of large-scale population screening,the National Health Commission has successively issued 5-in-1,10-in-1,and 20-in-1 mixed sampling technologies. However,the multiplication of preservation solution in the mixed sampling tube will result in virus dilution and increase the missed determination probability,and mixed sampling also aggravates the workload of epidemiological investigation and subsequent confirmation of the positive specimen in primary screening. With the progress of the COVID-19 epidemic,the SARS-CoV-2 continues to mutate,and the clinical laboratory determination technologies are gradually enriched and improved. Accurate analysis and judgment of the advantages and disadvantages of existing determination technologies and their application scenarios are conducive to the scientific prevention and control of the epidemic. This review will analyzes the following key clinical laboratory determination technical issues and put forward application suggestions,including the “mixed sampling” and “mixed determination” in nucleic acid determination,the impact of virus mutation on the performance of nucleic acid determination,the advantages and disadvantages of “endogenous” and “exogenous” internal standards in nucleic acid determination,the clinical significance and application scenarios of antigen determination and the value of antibody determination after vaccination.

Key words: Severe acute respiratory syndrome coronavirus-2, Clinical laboratory determination, Virus mutation, Analytical performance

中图分类号:

R446.1

欧铜, 张兵, 张秀明. 对新型冠状病毒实验室检测技术合理应用的再认识[J]. 检验医学, 2022, 37(4): 303-308.

OU Tong, ZHANG Bing, ZHANG Xiuming. Re-understanding about the rational application of clinical laboratory determination technologies for COVID-19 diagnosis[J]. Laboratory Medicine, 2022, 37(4): 303-308.

参考文献 27

[1]	国务院应对新型冠状病毒肺炎疫情联防联控机制医疗救治组. 关于印发新冠病毒核酸筛查稀释混样检测技术指引的通知[EB/OL]. (2020-07-22) [2020-07-30] http://www.nhc.gov.cn/yzygj/s7659/202007/90d971adb7e146bb8a4ad80c4c7c5eb0.shtml.
[2]	国务院应对新型冠状病毒肺炎疫情联防联控机制医疗救治组. 关于印发新冠病毒核酸10合1混采检测技术规范的通知[EB/OL]. (2020-08-19) [2020-08-30] http://www.nhc.gov.cn/yzygj/s7659/202008/fa5057afe4314ef8a9172edd6c65380e.shtml.
[3]	国务院应对新型冠状病毒肺炎疫情联防联控机制医疗救治组. 关于印发新冠病毒核酸20合1混采检测技术规范的通知[EB/OL]. (2022-01-17) [2022-01-30] http://www.nhc.gov.cn/yzygj/s7659/202201/4644a41bc9c14c5d888ca7c9e1f2f083.shtml.
[4]	罗颖, 陈晓辉, 李维, 等. 用于新冠肺炎大规模筛查和监测的混合样本采集策略[J]. 中国国境卫生检疫杂志, 2022, 45(1):34-36.
[5]	董宏杰, 张俊梅, 王帅, 等. 新型冠状病毒混合样品检测研究[J]. 山东大学学报(医学版), 2021, 59(4):1-5.
[6]	MISTRY P, BARMANIA F, MELLET J, et al. SARS-CoV-2 variants,vaccines,and host immunity[J]. Front Immunol, 2022, 12:809244.
[7]	张珂, 沈洁, 胡丽华. 新型冠状病毒变异株对新型冠状病毒疾病诊治及防疫的影响分析[J]. 外科研究与新技术, 2021, 10(3):203-208.
[8]	韩彦熙, 陈玉清, 李金明, 等. 全国新型冠状病毒德尔塔变异株核酸检测室间质量评价[J]. 中华医学杂志, 2022, 102(3):216-221.
[9]	ARTESI M, BONTEMS S, GÖBBELS P, et al. A recurrent mutation at position 26 340 of SARS-CoV-2 is associated with failure of the E gene quantitative reverse transcription-PCR utilized in a commercial dual-target diagnostic assay[J]. J Clin Microbiol, 2020, 58(10):e01598-20.
[10]	PEÑARRUBIA L, RUIZ M, PORCO R, et al. Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak[J]. Int J Infect Dis, 2020, 97:225-229. DOI URL
[11]	HERNANDEZ M M, BANU R, GONZALEZ-REICHE A S, et al. Robust clinical detection of SARS-CoV-2 variants by RT-PCR/MALDI-TOF multitarget approach[J]. J Med Virol, 2022, 94(4):1606-1616. DOI URL
[12]	GAND M, VANNESTE K, THOMAS I, et al. Deepening of in silico evaluation of SARS-CoV-2 detection RT-qPCR assays in the context of new variants[J]. Genes(Basel), 2021, 12(4):565.
[13]	国务院应对新型冠状病毒肺炎疫情联防联控机制综合组. 关于印发新冠病毒抗原检测应用方案(试行)的通知[EB/OL].(2022-03-10) [2022-03-30] http://www.nhc.gov.cn/yzygj/s7659/202203/d4d7fb72088447f7a4f9cd10966a67eb.shtml. .
[14]	国家卫生健康委员会办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒肺炎诊疗方案(试行第九版)的通知[EB/OL].(2022-03-14) [2022-03-30] http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml.
[15]	World Health Organization. Antigen detection in the diagnosis of SARS-CoV-2 infection[EB/OL].(2021-01-15) [2021-02-01] https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays.
[16]	SCHEIBLAUER H, FILOMENA A, NITSCHE A, et al. Comparative sensitivity evaluation for 122 CE-marked rapid diagnostic tests for SARS-CoV-2 antigen,Germany,September 2020 to April 2021[J]. Euro Surveill, 2021, 26(44):2100441.
[17]	BARO B, RODO P, OUCHI D, et al. Performance characteristics of five antigen-detecting rapid diagnostic test(Ag-RDT) for SARS-CoV-2 asymptomatic infection:a head-to-head benchmark comparison[J]. J Infect, 2021, 82(6):269-275. DOI URL
[18]	FU Y, PAN Y, LI Z, et al. The utility of specific antibodies against SARS-CoV-2 in laboratory diagnosis[J]. Front Microbiol, 2021, 11:603058.
[19]	MITTAL A, KHATTRI A, VERMA V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants[J]. PLoS Pathog, 2022, 18(2):e1010260.
[20]	鲁双艳, 吴琳, 刘成宇, 等. 新型冠状病毒特异性抗体IgM、IgG的临床意义[J]. 中国输血杂志, 2021, 34(8):861-864.
[21]	梁颖, 曾斯敏, 刘王亭, 等. 病毒特异性抗体检测在新型冠状病毒肺炎诊断中的应用价值[J]. 武汉大学学报(医学版), 2020, 41(5):693-696.
[22]	LI K, HUANG B, WU M, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19[J]. Nat Commun, 2020, 11(1):6044. DOI URL
[23]	汪建茹, 杨进波, 张驰. SARS-CoV-2抗体检测在新型冠状病毒肺炎诊断中的应用价值[J]. 检验医学, 2020, 35(6):546-550.
[24]	HANNAH R, EDOUARD M, LUCAS RG, et al. (Coronavirus pandemic(COVID-19)[EB/OL]. https://ourworld-indata.org/coronavirus.
[25]	TENBUSCH M, SCHUMACHER S, VOGEL E, et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2[J]. Lancet Infect Dis, 2021, 21(9):1212-1213. DOI URL
[26]	TADA T, ZHOU H, SAMANOVIC M I, et al. Neutralization of SARS-CoV-2 variants by mRNA and adenoviral vector vaccine-elicited antibodies[J]. Front Immunol, 2022, 13:797589.
[27]	DORIA-ROSE N, SUTHAR M S, MAKOWSKI M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for covid-19[J]. N Engl J Med, 2021, 384(23):2259-2261. DOI URL

对新型冠状病毒实验室检测技术合理应用的再认识

Re-understanding about the rational application of clinical laboratory determination technologies for COVID-19 diagnosis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

[1]	赵若楠, 盛哲, 叶志成, 杨丹, 余先智. 上海某儿科医院新型冠状病毒肺炎疫情前后腹泻患儿A组轮状病毒流行特征[J]. 检验医学, 2023, 38(9): 890-892.
[2]	杨雪, 朱俊, 蒋玲丽, 王青, 胡晓波. 上海地区9种新型冠状病毒核酸检测试剂盲样检测结果一致性分析[J]. 检验医学, 2023, 38(8): 776-780.
[3]	杜晶辉, 贺鑫, 刘晶, 刘瑞岩, 鲍志军, 王俊, 赵岩, 雷曜荣, 刘旻, 刘旭. 新型冠状病毒核酸检测7种振荡混匀方法效果评价[J]. 检验医学, 2023, 38(7): 680-685.
[4]	肖秀美, 梁超, 刘彩红, 李晓光. 新型冠状病毒中和抗体与特异性抗体检测结果一致性分析[J]. 检验医学, 2023, 38(4): 352-356.
[5]	李育敏, 付晓歌, 龚海娜, 郭东月, 曾子朗, 姚洁仪, 邓巧梅, 李双, 张秀明. 新型冠状病毒核酸检测假阴性和假阳性案例分析[J]. 检验医学, 2023, 38(4): 378-381.
[6]	李卫滨, 李瑞斌, 张胜行. 新型冠状病毒变异株生物学特性及其检测方法[J]. 检验医学, 2023, 38(4): 394-398.
[7]	曾艳芬, 吴泉明, 周欢, 张秋琴, 康艳丽, 李瑶, 陈喜军, 黄建刚, 陈发林. 一种新型冠状病毒核酸检测试剂在4个检测体系中的检出限分析[J]. 检验医学, 2023, 38(3): 261-266.
[8]	项瑾, 刘爱平, 胡尧, 吴之源, 曹国君, 关明. 新型冠状病毒肺炎患者抗核抗体谱分析和血清加热灭活对检测的影响[J]. 检验医学, 2023, 38(12): 1141-1146.
[9]	成宇, 徐臻, 陆柳, 丁梦蕾, 虞珊珊, 宗明, 范列英. 新型冠状病毒肺炎患者血清抗ACE-2抗体表达及其影响因素分析[J]. 检验医学, 2023, 38(12): 1147-1152.
[10]	刘洁, 刘业琼, 柯文才. 新型冠状病毒奥密克戎变异株感染早期病毒载量与实验室常规检测指标分析[J]. 检验医学, 2023, 38(12): 1202-1205.
[11]	魏瑞, 袁旭, 田学文, 鲁艳军. 武汉市某三级甲等医院人偏肺病毒感染患儿实验室检测结果和临床特征分析[J]. 检验医学, 2023, 38(1): 18-22.
[12]	杨丹平, 王宏, 王灿, 陈卫, 杨爱平. 新型冠状病毒抗原检测诊断效能和临床应用评价[J]. 检验医学, 2023, 38(1): 28-31.
[13]	姚晓宾, 许青霞, 王桢, 魏丹丹, 郑培明, 李刚. 新型冠状病毒区域筛查实验室结果上报经验分享[J]. 检验医学, 2023, 38(1): 76-77.
[14]	岳彩蝶, 李军燕, 丁爱军, 谢力, 曾韦锟. SARS-CoV-2抗原快速检测方法的研究进展[J]. 检验医学, 2023, 38(1): 87-93.
[15]	王善龙. 气膜方舱实验室大规模新型冠状病毒核酸筛查工作经验总结[J]. 检验医学, 2022, 37(9): 868-871.